Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Operating Income (2020 - 2025)

Bioventus (BVS) has disclosed Operating Income for 6 consecutive years, with $19.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 23.06% year-over-year to $19.5 million, compared with a TTM value of $54.0 million through Dec 2025, up 864.19%, and an annual FY2025 reading of $54.0 million, up 59.0% over the prior year.
  • Operating Income was $19.5 million for Q4 2025 at Bioventus, up from $11.3 million in the prior quarter.
  • Across five years, Operating Income topped out at $58.4 million in Q4 2022 and bottomed at -$126.8 million in Q4 2022.
  • Average Operating Income over 5 years is -$5.4 million, with a median of $4.8 million recorded in 2023.
  • Peak annual rise in Operating Income hit 1953.3% in 2022, while the deepest fall reached 12014.52% in 2022.
  • Year by year, Operating Income stood at -$3.2 million in 2021, then skyrocketed by 1953.3% to $58.4 million in 2022, then crashed by 91.86% to $4.8 million in 2023, then surged by 233.16% to $15.8 million in 2024, then increased by 23.06% to $19.5 million in 2025.
  • Business Quant data shows Operating Income for BVS at $19.5 million in Q4 2025, $11.3 million in Q3 2025, and $18.4 million in Q2 2025.